Shenzhen Cheng Da Biotechnology Investment Co., Ltd. (CDBIO (Shenzhen)) is a wholly-owned subsidiary of Liaoning Cheng Da Biotechnology Co., Ltd. established in September 2023 with a registered capital of 200 million yuan. CDBIO (Shenzhen) is headquartered at the CVC Innovation Center for Listed Companies in Xiangmihu, Futian District, Shenzhen (the first CVC innovation service park for listed companies in China).

As an external investment platform of CDBIO, CDBIO (Shenzhen) aims to achieve industrial linkage and coordinated development between the parent and subsidiary companies mainly through investment, incubation, mergers and acquisitions (M&A), and business development within the biomedical and healthcare industry chain.

Moreover, CDBIO (Shenzhen) serves as a vital window for CDBIO's external exchanges in the capital market and the Guangdong-Hong Kong-Macao Greater Bay Area to enhance the communication and the interaction with domestic and overseas investment research institutions, scientific research institutions, innovative enterprises, and other market players, thus promoting the continuous improvement of CDBIO's corporate governance and overall company value.